Kaiser Permanente Approves Commercial Use of Cxbladder

Company Announcement
17 June 2020


KAISER PERMANENTE APPROVES COMMERCIAL USE OF CXBLADDER


Cancer diagnostics company, Pacific Edge Limited (NZX: PEB) and US healthcare provider, Kaiser Permanente,
have reached agreement for the commercial use of Pacific Edge’s Cxbladder tests.

Kaiser Permanente has approved the commercial use of Cxbladder by their urologists for patients being
evaluated for bladder cancer.

Kaiser Permanente is one of the largest non-profit healthcare providers in the US, with over 12 million
members. It operates 39 hospitals and employs approximately 23,000 physicians.

Cxbladder urine sampling systems will be sent directly to Kaiser Permanente patients in their homes for
onward delivery to Pacific Edge’s US laboratory in Pennsylvania for analysis and reporting. Kaiser Permanente
patients will also have the ability to provide a urine sample at one of the many Kaiser Permanente sample
collection clinics for onward delivery to Pacific Edge for analysis and reporting.

Cxbladder’s ability to provide for the collection of the urine sample in-home will allow Kaiser Permanente
patients to be regularly tested for bladder cancer at home and will also enable their physicians to do more
patient management using tele-consultation. Based on the test results, many patients will also be able to
avoid having any further invasive procedures. This has obvious benefits for patients and also frees up
essential healthcare capacity for Kaiser Permanente.

Kaiser Permanente has previously completed a successful Cxbladder User Programme, including in-home
sample collection. The Pacific Edge team has been working with Kaiser Permanente’s staff on the necessary
business logistics and the training which will ensure that start-up of commercial tests can occur as
expediently as possible.

CEO of Pacific Edge, David Darling, said: “We are delighted to be working with Kaiser Permanente to
implement the delivery of Cxbladder into their patient care program for urology. This outcome highlights
Kaiser Permanente’s recognised position as an industry leader in their approach to high-quality healthcare,
innovation and value-based medicine.”

“The clinical utility provided by the Cxbladder in-home sampling programme has also been recognised in both
the USA and New Zealand. In New Zealand, three large public healthcare providers have been actively using
Cxbladder for in-home sample collection and two public healthcare providers have moved to mainstream
commercial use of two Cxbladder products. Remote consultations and the ability for patients to supply
Cxbladder test samples from home will help protect patients and frees up essential capacity for healthcare
providers around the world, both during the COVID-19 global pandemic and beyond.”

ENDS

For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

Company Announcement
17 June 2020


OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery
and commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder
suite of non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and
management of urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder
cancer tests globally through its wholly owned central laboratories in New Zealand and the USA. The company’s
products have been tested and validated in international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of
patients with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who
have a low probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of
a patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence
of the cancer as an effective adjunct to cystoscopy.

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer
has a recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients
with a prior history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of
recurrent urothelial carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in
the management of patients for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer.
Cxbladder Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other
Cxbladder tests (Triage, Detect), is designed to assist clinicians by accurately identifying patients with a high probability
of having high grade or late stage bladder cancer, for whom alternative or expedited treatment options may be
warranted, or who can be prioritised for further investigation in high throughput settings.

Refer to www.cxbladder.com for more information.